A new genomic framework has been developed to categorize pediatric acute myeloid leukemia, which may enable new treatment possibilities. The framework is based on research into the genetic and epigenetic characteristics of the disease, including the role of specific mutations and gene expression. Studies have examined the genomic landscape of pediatric acute myeloid leukemia in various contexts, including its relationship to other conditions and its potential for targeted treatment.